Or­biMed, J&J back $24M A round for mi­cro­bio­me start­up; Sang­amo, Pfiz­er win FDA fast track

→ A new mi­cro­bio­me start­up, Is­rael’s Bio­mX, has raised $24 mil­lion in a Se­ries A — Or­biMed, John­son & John­son In­no­va­tion and Take­da Ven­tures were in on the round, with par­tic­i­pa­tion from Sev­en­ture Part­ners, Mi­rae­As­set, SBI Japan-Is­rael In­no­va­tion Fund and oth­er Eu­ro­pean in­vestors. Bio­mX is a pre­clin­i­cal biotech set­ting the stage for its first hu­man study in the field of gut bi­ol­o­gy, which has at­tract­ed a num­ber of new play­ers over the past few years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.